IAP-0971 by Sunho (China) Biopharmaceutical for Cervical Cancer: Likelihood of Approval

Share this article

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IAP-0971 overview

IAP-0971 is under development for the treatment of solid tumor, lung cancer, cervical cancer, head and neck squamous cell carcinoma, liver cancer, non muscle invasive bladder cancer (NMIBC) and non-Hodgkin lymphoma. The drug candidate is administered through subcutaneous route. It acts by targeting PD1 and IL15. It is being developed based on Armed ImmunoCytokine (AIC) platform.

Sunho (China) Biopharmaceutical overview

Sunho (China) Biopharmaceutical (Sunho (China) Biopharmaceutical) is a healthcare service provider. It specializes in developing drugs for the treatment of cancer. Sunho (China) Biopharmaceutical is headquartered in Chengdu, China.

For a complete picture of IAP-0971’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 1 January 1970

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.